Thorvardur Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine and President Emeritus at North American Neuroendocrine Tumor Society, shared a post on X:
“The results of the COMPETE trial (LU-177 DOTATOC vs. everolimus is mostly second line therapy (small subset 1st line).
Radioligand therapy superior to everolimus.”
You can also read: ESMO 2025 Day 1 Highlights Not to Miss.
